Owner Investor / Financier Operator Developer Technology licensor Technology / equipment supplier
Wacker Chemie AG (branded as WACKER) is a global specialty chemicals company headquartered in Munich, Germany. Founded in 1914, it develops and manufactures materials and solutions for industrial and consumer applications. The company operates four main business divisions: WACKER Silicones, WACKER Polymers, WACKER Polysilicon, and WACKER BIOSOLUTIONS. WACKER Biotech GmbH is the group’s contract development and manufacturing organization for biopharmaceuticals.
WACKER’s portfolio includes silicones and silanes; polymer binders such as vinyl acetate-ethylene (VAE) dispersions and dispersible polymer powders for construction and coatings; and hyperpure polysilicon used in semiconductors and photovoltaics. Its biosolutions activities focus on microbial fermentation and related services for pharmaceuticals and life sciences. The company serves markets including construction, automotive, electronics, energy, healthcare, and consumer goods, and operates a global production network with major sites in Germany and facilities across Europe, the Americas, and Asia.
Also known as Wacker Chemie AG, Wacker Chemie, Wacker Biotech GmbH, Wacker Biotech, and WACKER Group.
chemXplore tracks 23 projects involving WACKER, of which 2 are active.
Besides these 2, the record holds 20 completed projects and 1 cancelled.
Closest to start-up first.
The 21 that are completed, on hold or cancelled are in the record. See all 23 in chemXplore →
Showcase of silicone emulsions, resins and waxes for textiles, surfaces and automotive care; bio-based emollient and aminolipid debut; demos and presentations in Berlin.
Two new LSR grades: a self-adhesive, high-tear, non-postcure overmolding grade and an oil-exuding, coolant‑resistant sealant for EV battery cooling circuits.
Selective growth in electronics, healthcare and mobility; €300–€400m annual investment; PACE to save >€300m/year from 2028; Net Zero by 2045.
EU approval allows plant‑based, fermented L‑cysteine/L‑cystine as sensory additives for all animal species; products suit multiple dosage forms and are supplied from Europe.
Combines AI-driven sequence design and sequencing analytics with GMP-compliant pDNA/IVT and LNP manufacturing to offer clinic-ready RNA supply chains.
Q2 sales €1.52bn; EBITDA €211m aided by cost cuts and a €36.7m pension revaluation; net income includes €243m from Siltronic sale; full‑year guidance adjusted.
First production line started after two years; facility will supply customized silicones for electromobility, healthcare, appliances and energy markets.
Ceramifying silicone boosts thermal and flame resistance in battery barriers; potting compounds deliver 1.6 and 2.4 W/mK, low sedimentation and room‑temperature cure.
active all projects
What each is building and closing, and the pipelines and grids between them, on one map.
